Insider Buying: Janux Therapeutics, Inc. (NASDAQ:JANX) Director Purchases 110,206 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) Director Ra Capital Management, L.P. bought 110,206 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, March 5th, Ra Capital Management, L.P. purchased 341,742 shares of Janux Therapeutics stock. The stock was bought at an average cost of $30.64 per share, with a total value of $10,470,974.88.

Janux Therapeutics Price Performance

NASDAQ JANX traded down $0.73 on Tuesday, hitting $29.49. 453,113 shares of the stock were exchanged, compared to its average volume of 817,161. The company's 50-day moving average price is $40.83 and its two-hundred day moving average price is $47.40. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -24.95 and a beta of 3.23. Janux Therapeutics, Inc. has a 52-week low of $28.96 and a 52-week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Remove Ads

Analyst Ratings Changes

JANX has been the subject of a number of research reports. Stifel Nicolaus increased their price target on Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. Wedbush reaffirmed an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Cantor Fitzgerald restated an "overweight" rating and set a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Finally, Leerink Partnrs upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and an average target price of $88.00.

Institutional Trading of Janux Therapeutics

Institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. grew its stake in Janux Therapeutics by 143.4% in the third quarter. Victory Capital Management Inc. now owns 29,745 shares of the company's stock valued at $1,351,000 after purchasing an additional 17,525 shares in the last quarter. Plato Investment Management Ltd lifted its stake in shares of Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after purchasing an additional 187 shares during the last quarter. Intech Investment Management LLC bought a new stake in Janux Therapeutics in the third quarter worth $368,000. Charles Schwab Investment Management Inc. raised its holdings in Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock valued at $10,639,000 after buying an additional 156,675 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Janux Therapeutics in the third quarter worth about $1,112,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.